AstraZeneca reports positive results from phase IIIb trial of benralizumab in severe eosinophilic asthma patients

When added to standard of care, benralizumab was reported to be linked to statistically significant 49% reduction in annual rate of asthma exacerbation compared to placebo, in patients with baseline blood eosinophil counts higher than or equal to 150 cells per microlitre.